Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.06 USD | -2.77% |
|
-26.39% | -37.58% |
07-03 | Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38 | MT |
07-02 | Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.58% | 980M | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38